Natural history of hepatitis C and outcomes following liver transplantation

Minerva Gastroenterologica e Dietologica

Volumn 50, Issue 1, 2004, Pages 51-59

  Rodriguez Luna, H ^a   Vargas, H E ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC HOSPITAL   (United States)

Author keywords

Hepatitis C; Liver transplantation; Recurrence

Indexed keywords

AUSTRALIA; DEATH; DISEASE COURSE; DISEASE SEVERITY; EUROPE; GRAFT CIRRHOSIS; GRAFT FAILURE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; OUTCOMES RESEARCH; POSTOPERATIVE PERIOD; RECURRENT INFECTION; REOPERATION; REVIEW; RISK FACTOR; SURVIVAL RATE; TREATMENT INDICATION; UNITED STATES;

HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 2442550696     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. Hepatology 1997;26:521-6.
2. Hepatitis C 2002. Vol. 2004: World Health organization: http://www.who.int/ith/chapter05_m05_hepatitis.htlm.
3. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340:1228-33.
4. Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason KD, Smoak BL et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-11.
5. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-8.
6. Wong JB. Cost-effectiveness of treatments for chronic hepatitis C. Am J Med 1999;107:74S-8.
7. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:62S-5.
8. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997;26:34S-8.
9. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16.
10. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002;36:227-42.
11. McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl 2002;8:S7-13.
12. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;9:S1-9.
13. Boker KH, Dalley G, Bahr MJ, Maschek H, Tillmann HL, Trautwein C et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997;25:203-10.
14. Guerrero RB, Batts KP, Burgart LJ, Barrett SL, Germer JJ, Poterucha JJ et al. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol 2000; 13:229-37.
15. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-77.
16. Ballardini G, De Raffele E, Groff P, Bioulac-Sage P, Grassi A, Ghetti S et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl 2002; 8:10-20.
17. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680-7.
18. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, Batts K, Moreno-Luna L, Poterucha J et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32:1125-30.
19. Gretch DR, Bacchi CE, Corey L, dela Rosa C, Lesniewski RR, Kowdley K et al. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology 1995;22:1-9.
20. Zhou S, Terrault NA, Ferrell L, Hahn JA, Lau JY, Simmonds P et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996;24:1041-6.
21. Konig V, Bauditz J, Lobeck H, Neuhaus P, Blumhardt G, Bechstein WO et al. Hepatitis C virus reinfection in allografts after orthotopic liver transplantation. Hepatology 1992;16:1137-43.
22. Chazouilleres O, Kim M, Combs C, Ferrell L, Bacchetti P, Roberts J et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106:994-9.
23. Doughty AL, Spencer JD, Cossart YE, McCaughan GW. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. Liver Transpl Surg 1998;4:15-21.
24. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003;9:S28-34.
25. Weinstein JS, Poterucha JJ, Zein N, Wiesner RH, Persing DH, Rakela J. Epidemiology and natural history of hepatitis C infections in liver transplant recipients. J Hepatol 1995;22:154-9.
26. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996;23:971-6.
27. Dickson RC, Caldwell SH, Ishitani MB, Lau JY, Driscoll CJ, Stevenson WC et al. Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation 1996;61:701-5.
28. Pessoa MG, Bzowej N, Berenguer M, Phung Y, Kim M, Ferrell L et al. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999;30: 1513-20.
29. Arenas JI, Gallegos-Orozco JF, Laskus T et al. Hepatitis C virus quasispecies dynamics predict fibrosis progression after liver transplantation. J Infect Dis 2004. In press 2004.
30. Zekry A, Bishop GA, Bowen DG, Gleeson MM, Guney S, Painter DM et al. Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury. Liver Transpl 2002;8:292-301.
31. McCaughan GW, Zekry A. Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. Transpl Infect Dis 2000;2:166-85.
32. Sreekumar R, Rasmussen DL, Wiesner RH, Charlton MR. Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation. Liver Transpl 2002;8:814-21.
33. Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 2000;6:44-53.
34. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-20.
35. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D et al. High incidence of allograft cirrhosis in hepatitis C virus genotype lb infection following transplantation: relationship with rejection episodes. Hepatology 1999;29:250-6.
36. Berenguer M, Rayon JM, Prieto M, Aguilera V, Nicolas D, Ortiz V et al. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl 2001; 7:790-6.
37. Slapak GI, Saxena R, Portmann B, Gane E, Devlin J, Calne R et al. Graft and systemic disease in long-term survivors of liver transplantation. Hepatology 1997; 25:195-202.
38. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-10.
39. Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999;117:619-25.
40. Sanchez-Fueyo A, Restrepo JC, Quinto L, Bruguera M, Grande L, Sanchez-Tapias JM et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002;73:56-63.
41. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
42. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673-84.
43. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666-78.
44. Feray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994;20:1137-43.
45. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32:852-8.
46. Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001;7:811-5.
47. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
48. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-96.
49. Taniguchi M, Wachs M, Bak T, Trotter J, Kugelmans M, Everson G et al. Hepatitis C recurrence in living donor liver transplantation. Am J Transpl 2002;2 Suppl 3:49.
50. Rodriguez-Luna H, Vargas H, DePetris G, Byrne T, Moss A, Mulligan D et al. Hepatitis C recurrence in living donor liver transplantation. Am J Transpl 2003;3: 160A.
51. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-30.
52. Everhart JE, Wei Y, Eng H, Charlton MR, Persing DH, Wiesner RH et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999; 29:1220-6.
53. Rodriguez-Luna H, Byrne T, Balan V, Rakela J, Vargas HE. Hepatocellular carcinoma with and without hepatitis C virus infection, a controversial indication for liver transplantation: maybe not! Hepatology 2003; 38:325A.
54. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248-52.
55. Vargas HE, Laskus T, Wang LF, Lee R, Radkowski M, Dodson F et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 1999; 117:149-53.
56. Vargas HE, Laskus T, Wang LF, Radkowski M, Poutous A, Lee R et al. The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg 1998;4:22-7.
57. Chopra KB, Demetris AJ, Blakolmer K, Dvorchik I, Laskus T, Wang LF et al. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 2003;76:1487-91.
58. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002;8:362-9.
59. Brillanti S, Vivarelli M, De Ruvo N, Aden AA, Camaggi V, D'Errico A et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002;8:884-8.
60. Crippin JS, McCashland T, Terrault N, Sheiner: P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-5.
61. Everson GT, Trotter JF, Kugelmas M. Long-term outcomes of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol (low dose accelerating-dose regimen). Hepatology 2002;36:279A.
62. Fukumoto T, Berg T, Ku Y, Bechstein WO, Knoop M, Lemmens HP et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 1996;24:1351-4.
63. Shiffman ML, Vargas HE, Everson GT. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transpl 2003;9:1129-44.
64. Lavezzo B, Rizzetto M. Treatment of recurrent hepatitis C virus infection after liver transplantation. J Hepatol 1999;31 Suppl 1:222-6.
65. Shakil AO, McGuire B, Crippin J, Teperman L, Demetris AJ, Conjeevaram H et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002; 36:1253-8.
66. Narayanan Menon KV, Poterucha JJ, El-Amin OM, Burgart LJ, Kremers WK, Rosen CB et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002;8:623-9.
67. Feray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995; 22:1084-9.
68. Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JY, Naoumov NV et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998;27:1403-7.
69. Singh N, Gayowski T, Wannstedt CF, Marino IR, Wagener MM. Interferon-alpha therapy for hepatitis C virus recurrence after liver transplantation: long-term response with maintenance therapy. Clin Transplant 1996;10:348-51.
70. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:591-8.
71. Cotler SJ, Ganger DR, Kaur S, Rosenblate H, Jakate S, Sullivan DG et al. Daily interferon therapy for hepatitis C virus infection in liver transplant recipients. Transplantation 2001;71:261-6.
72. Wright TL, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994;20:773-9.
73. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997;26:473-7.
74. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124:642-50.
75. Rodriguez-Luna H, Kratio A, Sharma P, De Petris G, Williams J, Ortiz J, Hansen K et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of of pegylated interferon alpha2b and ribavirin: an open label series. Transplantation 2004;77: 190-4.
76. Neuberger J. Treatment of hepatitis C virus infection in the allograft. Liver Transpl 2003;9:S101-8.
77. Biggins SW, Beldecos A, Rabkin JM, Rosen HR. Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations. Liver Transpl 2002;8:313-22.
78. Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998;66:1612-6.
79. Markmann JF, Markowitz JS, Yersiz H, Morrisey M, Farmer DG, Farmer DA et al. Long-term survival after retransplantation of the liver. Ann Surg 1997;226:408-18; discussion 418-20.